多発性硬化症治療薬の世界市場（～2026年）

• 英文タイトル：Global Multiple Sclerosis Therapeutics Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY03866
• 出版社/出版日：QYResearch / 2020年11月20日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、95ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：医療、製薬

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料は多発性硬化症治療薬のグローバル市場について調査・分析したレポートです。種類別（ベータインターフェロン、コルチコステロイド、モノクローナル抗体、抗腫瘍剤、その他）市場規模、用途別（病院薬局、小売薬局、eコマース）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別多発性硬化症治療薬の競争状況、市場シェア
・世界の多発性硬化症治療薬市場：種類別市場規模 2015年-2020年（ベータインターフェロン、コルチコステロイド、モノクローナル抗体、抗腫瘍剤、その他）
・世界の多発性硬化症治療薬市場：種類別市場規模予測 2021年-2026年（ベータインターフェロン、コルチコステロイド、モノクローナル抗体、抗腫瘍剤、その他）
・世界の多発性硬化症治療薬市場：用途別市場規模 2015年-2020年（病院薬局、小売薬局、eコマース）
・世界の多発性硬化症治療薬市場：用途別市場規模予測 2021年-2026年（病院薬局、小売薬局、eコマース）
・北米の多発性硬化症治療薬市場分析：米国、カナダ
・ヨーロッパの多発性硬化症治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの多発性硬化症治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の多発性硬化症治療薬市場分析：メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの多発性硬化症治療薬市場分析：トルコ、サウジアラビア、UAE等
・企業情報（企業概要、製品概要、販売量、企業動向）
- 掲載企業（変更可能性あり）：Novartis、Teva Pharmaceuticals、Sanofi Genzyme、Bayer、Pfizer、Biogen Idec、Merck、AbbVie
・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system). In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body. Eventually, the disease can cause the nerves themselves to deteriorate or become permanently damaged.

Market Analysis and Insights: Global Multiple Sclerosis Therapeutics Market
The global Multiple Sclerosis Therapeutics market size is projected to reach US$ 17400 million by 2026, from US$ 17030 million in 2020, at a CAGR of 2.0%% during 2021-2026.

Global Multiple Sclerosis Therapeutics Scope and Market Size
Multiple Sclerosis Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Multiple Sclerosis Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Novartis
Teva Pharmaceuticals
Sanofi Genzyme
Bayer
Pfizer
Biogen Idec
Merck
AbbVie

Market segment by Type, the product can be split into
Beta Interferon
Corticosteroids
Monoclonal Antibodies
Antineoplastic Agents
Others
Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies
e-Commerce

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Multiple Sclerosis Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Multiple Sclerosis Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Beta Interferon
1.4.3 Corticosteroids
1.4.4 Monoclonal Antibodies
1.4.5 Antineoplastic Agents
1.4.6 Others
1.5 Market by Application
1.5.1 Global Multiple Sclerosis Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 e-Commerce
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Multiple Sclerosis Therapeutics Market Perspective (2015-2026)
2.2 Global Multiple Sclerosis Therapeutics Growth Trends by Regions
2.2.1 Multiple Sclerosis Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Multiple Sclerosis Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Multiple Sclerosis Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Multiple Sclerosis Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Multiple Sclerosis Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Multiple Sclerosis Therapeutics Players by Market Size
3.1.1 Global Top Multiple Sclerosis Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Multiple Sclerosis Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Multiple Sclerosis Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Multiple Sclerosis Therapeutics Market Concentration Ratio
3.2.1 Global Multiple Sclerosis Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Multiple Sclerosis Therapeutics Revenue in 2019
3.3 Multiple Sclerosis Therapeutics Key Players Head office and Area Served
3.4 Key Players Multiple Sclerosis Therapeutics Product Solution and Service
3.5 Date of Enter into Multiple Sclerosis Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Multiple Sclerosis Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Multiple Sclerosis Therapeutics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Multiple Sclerosis Therapeutics Market Size by Application (2015-2020)
5.2 Global Multiple Sclerosis Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Multiple Sclerosis Therapeutics Market Size (2015-2020)
6.2 Multiple Sclerosis Therapeutics Key Players in North America (2019-2020)
6.3 North America Multiple Sclerosis Therapeutics Market Size by Type (2015-2020)
6.4 North America Multiple Sclerosis Therapeutics Market Size by Application (2015-2020)

7 Europe
7.1 Europe Multiple Sclerosis Therapeutics Market Size (2015-2020)
7.2 Multiple Sclerosis Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Multiple Sclerosis Therapeutics Market Size by Type (2015-2020)
7.4 Europe Multiple Sclerosis Therapeutics Market Size by Application (2015-2020)

8 China
8.1 China Multiple Sclerosis Therapeutics Market Size (2015-2020)
8.2 Multiple Sclerosis Therapeutics Key Players in China (2019-2020)
8.3 China Multiple Sclerosis Therapeutics Market Size by Type (2015-2020)
8.4 China Multiple Sclerosis Therapeutics Market Size by Application (2015-2020)

9 Japan
9.1 Japan Multiple Sclerosis Therapeutics Market Size (2015-2020)
9.2 Multiple Sclerosis Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Multiple Sclerosis Therapeutics Market Size by Type (2015-2020)
9.4 Japan Multiple Sclerosis Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Multiple Sclerosis Therapeutics Market Size (2015-2020)
10.2 Multiple Sclerosis Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Multiple Sclerosis Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Multiple Sclerosis Therapeutics Market Size by Application (2015-2020)

11 India
11.1 India Multiple Sclerosis Therapeutics Market Size (2015-2020)
11.2 Multiple Sclerosis Therapeutics Key Players in India (2019-2020)
11.3 India Multiple Sclerosis Therapeutics Market Size by Type (2015-2020)
11.4 India Multiple Sclerosis Therapeutics Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Multiple Sclerosis Therapeutics Market Size (2015-2020)
12.2 Multiple Sclerosis Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Multiple Sclerosis Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Multiple Sclerosis Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Novartis
13.1.1 Novartis Company Details
13.1.2 Novartis Business Overview
13.1.3 Novartis Multiple Sclerosis Therapeutics Introduction
13.1.4 Novartis Revenue in Multiple Sclerosis Therapeutics Business (2015-2020))
13.1.5 Novartis Recent Development
13.2 Teva Pharmaceuticals
13.2.1 Teva Pharmaceuticals Company Details
13.2.2 Teva Pharmaceuticals Business Overview
13.2.3 Teva Pharmaceuticals Multiple Sclerosis Therapeutics Introduction
13.2.4 Teva Pharmaceuticals Revenue in Multiple Sclerosis Therapeutics Business (2015-2020)
13.2.5 Teva Pharmaceuticals Recent Development
13.3 Sanofi Genzyme
13.3.1 Sanofi Genzyme Company Details
13.3.2 Sanofi Genzyme Business Overview
13.3.3 Sanofi Genzyme Multiple Sclerosis Therapeutics Introduction
13.3.4 Sanofi Genzyme Revenue in Multiple Sclerosis Therapeutics Business (2015-2020)
13.3.5 Sanofi Genzyme Recent Development
13.4 Bayer
13.4.1 Bayer Company Details
13.4.2 Bayer Business Overview
13.4.3 Bayer Multiple Sclerosis Therapeutics Introduction
13.4.4 Bayer Revenue in Multiple Sclerosis Therapeutics Business (2015-2020)
13.4.5 Bayer Recent Development
13.5 Pfizer
13.5.1 Pfizer Company Details
13.5.2 Pfizer Business Overview
13.5.3 Pfizer Multiple Sclerosis Therapeutics Introduction
13.5.4 Pfizer Revenue in Multiple Sclerosis Therapeutics Business (2015-2020)
13.5.5 Pfizer Recent Development
13.6 Biogen Idec
13.6.1 Biogen Idec Company Details
13.6.2 Biogen Idec Business Overview
13.6.3 Biogen Idec Multiple Sclerosis Therapeutics Introduction
13.6.4 Biogen Idec Revenue in Multiple Sclerosis Therapeutics Business (2015-2020)
13.6.5 Biogen Idec Recent Development
13.7 Merck
13.7.1 Merck Company Details
13.7.2 Merck Business Overview
13.7.3 Merck Multiple Sclerosis Therapeutics Introduction
13.7.4 Merck Revenue in Multiple Sclerosis Therapeutics Business (2015-2020)
13.7.5 Merck Recent Development
13.8 AbbVie
13.8.1 AbbVie Company Details
13.8.2 AbbVie Business Overview
13.8.3 AbbVie Multiple Sclerosis Therapeutics Introduction
13.8.4 AbbVie Revenue in Multiple Sclerosis Therapeutics Business (2015-2020)
13.8.5 AbbVie Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Multiple Sclerosis Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Multiple Sclerosis Therapeutics Revenue
Table 3. Ranking of Global Top Multiple Sclerosis Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Multiple Sclerosis Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Beta Interferon
Table 6. Key Players of Corticosteroids
Table 7. Key Players of Monoclonal Antibodies
Table 8. Key Players of Antineoplastic Agents
Table 9. Key Players of Others
Table 10. Global Multiple Sclerosis Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Multiple Sclerosis Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Multiple Sclerosis Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Multiple Sclerosis Therapeutics Market Share by Regions (2015-2020)
Table 14. Global Multiple Sclerosis Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Multiple Sclerosis Therapeutics Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Multiple Sclerosis Therapeutics Market Growth Strategy
Table 20. Main Points Interviewed from Key Multiple Sclerosis Therapeutics Players
Table 21. Global Multiple Sclerosis Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 22. Global Multiple Sclerosis Therapeutics Market Share by Players (2015-2020)
Table 23. Global Top Multiple Sclerosis Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Multiple Sclerosis Therapeutics as of 2019)
Table 24. Global Multiple Sclerosis Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Multiple Sclerosis Therapeutics Product Solution and Service
Table 27. Date of Enter into Multiple Sclerosis Therapeutics Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Multiple Sclerosis Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 30. Global Multiple Sclerosis Therapeutics Market Size Share by Type (2015-2020)
Table 31. Global Multiple Sclerosis Therapeutics Revenue Market Share by Type (2021-2026)
Table 32. Global Multiple Sclerosis Therapeutics Market Size Share by Application (2015-2020)
Table 33. Global Multiple Sclerosis Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 34. Global Multiple Sclerosis Therapeutics Market Size Share by Application (2021-2026)
Table 35. North America Key Players Multiple Sclerosis Therapeutics Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Multiple Sclerosis Therapeutics Market Share (2019-2020)
Table 37. North America Multiple Sclerosis Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 38. North America Multiple Sclerosis Therapeutics Market Share by Type (2015-2020)
Table 39. North America Multiple Sclerosis Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 40. North America Multiple Sclerosis Therapeutics Market Share by Application (2015-2020)
Table 41. Europe Key Players Multiple Sclerosis Therapeutics Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Multiple Sclerosis Therapeutics Market Share (2019-2020)
Table 43. Europe Multiple Sclerosis Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Multiple Sclerosis Therapeutics Market Share by Type (2015-2020)
Table 45. Europe Multiple Sclerosis Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Multiple Sclerosis Therapeutics Market Share by Application (2015-2020)
Table 47. China Key Players Multiple Sclerosis Therapeutics Revenue (2019-2020) (Million US$)
Table 48. China Key Players Multiple Sclerosis Therapeutics Market Share (2019-2020)
Table 49. China Multiple Sclerosis Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 50. China Multiple Sclerosis Therapeutics Market Share by Type (2015-2020)
Table 51. China Multiple Sclerosis Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 52. China Multiple Sclerosis Therapeutics Market Share by Application (2015-2020)
Table 53. Japan Key Players Multiple Sclerosis Therapeutics Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Multiple Sclerosis Therapeutics Market Share (2019-2020)
Table 55. Japan Multiple Sclerosis Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Multiple Sclerosis Therapeutics Market Share by Type (2015-2020)
Table 57. Japan Multiple Sclerosis Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Multiple Sclerosis Therapeutics Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Multiple Sclerosis Therapeutics Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Multiple Sclerosis Therapeutics Market Share (2019-2020)
Table 61. Southeast Asia Multiple Sclerosis Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Multiple Sclerosis Therapeutics Market Share by Type (2015-2020)
Table 63. Southeast Asia Multiple Sclerosis Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Multiple Sclerosis Therapeutics Market Share by Application (2015-2020)
Table 65. India Key Players Multiple Sclerosis Therapeutics Revenue (2019-2020) (Million US$)
Table 66. India Key Players Multiple Sclerosis Therapeutics Market Share (2019-2020)
Table 67. India Multiple Sclerosis Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 68. India Multiple Sclerosis Therapeutics Market Share by Type (2015-2020)
Table 69. India Multiple Sclerosis Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 70. India Multiple Sclerosis Therapeutics Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Multiple Sclerosis Therapeutics Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Multiple Sclerosis Therapeutics Market Share (2019-2020)
Table 73. Central & South America Multiple Sclerosis Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Multiple Sclerosis Therapeutics Market Share by Type (2015-2020)
Table 75. Central & South America Multiple Sclerosis Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Multiple Sclerosis Therapeutics Market Share by Application (2015-2020)
Table 77. Novartis Company Details
Table 78. Novartis Business Overview
Table 79. Novartis Product
Table 80. Novartis Revenue in Multiple Sclerosis Therapeutics Business (2015-2020) (Million US$)
Table 81. Novartis Recent Development
Table 82. Teva Pharmaceuticals Company Details
Table 83. Teva Pharmaceuticals Business Overview
Table 84. Teva Pharmaceuticals Product
Table 85. Teva Pharmaceuticals Revenue in Multiple Sclerosis Therapeutics Business (2015-2020) (Million US$)
Table 86. Teva Pharmaceuticals Recent Development
Table 87. Sanofi Genzyme Company Details
Table 88. Sanofi Genzyme Business Overview
Table 89. Sanofi Genzyme Product
Table 90. Sanofi Genzyme Revenue in Multiple Sclerosis Therapeutics Business (2015-2020) (Million US$)
Table 91. Sanofi Genzyme Recent Development
Table 92. Bayer Company Details
Table 93. Bayer Business Overview
Table 94. Bayer Product
Table 95. Bayer Revenue in Multiple Sclerosis Therapeutics Business (2015-2020) (Million US$)
Table 96. Bayer Recent Development
Table 97. Pfizer Company Details
Table 98. Pfizer Business Overview
Table 99. Pfizer Product
Table 100. Pfizer Revenue in Multiple Sclerosis Therapeutics Business (2015-2020) (Million US$)
Table 101. Pfizer Recent Development
Table 102. Biogen Idec Company Details
Table 103. Biogen Idec Business Overview
Table 104. Biogen Idec Product
Table 105. Biogen Idec Revenue in Multiple Sclerosis Therapeutics Business (2015-2020) (Million US$)
Table 106. Biogen Idec Recent Development
Table 107. Merck Company Details
Table 108. Merck Business Overview
Table 109. Merck Product
Table 110. Merck Revenue in Multiple Sclerosis Therapeutics Business (2015-2020) (Million US$)
Table 111. Merck Recent Development
Table 112. AbbVie Business Overview
Table 113. AbbVie Product
Table 114. AbbVie Company Details
Table 115. AbbVie Revenue in Multiple Sclerosis Therapeutics Business (2015-2020) (Million US$)
Table 116. AbbVie Recent Development
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Multiple Sclerosis Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Beta Interferon Features
Figure 3. Corticosteroids Features
Figure 4. Monoclonal Antibodies Features
Figure 5. Antineoplastic Agents Features
Figure 6. Others Features
Figure 7. Global Multiple Sclerosis Therapeutics Market Share by Application: 2020 VS 2026
Figure 8. Hospital Pharmacies Case Studies
Figure 9. Retail Pharmacies Case Studies
Figure 10. e-Commerce Case Studies
Figure 11. Multiple Sclerosis Therapeutics Report Years Considered
Figure 12. Global Multiple Sclerosis Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Multiple Sclerosis Therapeutics Market Share by Regions: 2020 VS 2026
Figure 14. Global Multiple Sclerosis Therapeutics Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Multiple Sclerosis Therapeutics Market Share by Players in 2019
Figure 17. Global Top Multiple Sclerosis Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Multiple Sclerosis Therapeutics as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Multiple Sclerosis Therapeutics Revenue in 2019
Figure 19. North America Multiple Sclerosis Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Multiple Sclerosis Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Multiple Sclerosis Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Multiple Sclerosis Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Multiple Sclerosis Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Multiple Sclerosis Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Multiple Sclerosis Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Bottom-up and Top-down Approaches for This Report
Figure 27. Data Triangulation
Figure 28. Key Executives Interviewed

以下、関連資料のご紹介

多発性硬化症における幹細胞治療の世界市場（～2026年）

Global Stem Cell Therapy for Multiple Sclerosis Market Size, Status and Forecast 2020-2026
MRC2-11QY04730 2020年11月20日 97Pages
当調査資料は多発性硬化症における幹細胞治療のグローバル市場について調査・分析したレポートです。種類別（静脈内、脳室内）市場規模、用途別（再発寛解型多発性硬化症（RRMS）、一次進行型多発性硬化症（PPMS）、二次性進行型多発性硬化症（SPMS）、進行型再発性多発性硬化症（PRMS））市場規模、地域別...

多発性硬化症治療の世界市場（～2026年）

Global Multiple Sclerosis Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY03867 2020年11月20日 99Pages
当調査資料は多発性硬化症治療のグローバル市場について調査・分析したレポートです。種類別（磁気共鳴画像法、簡易電気刺激検査、腰椎穿刺）市場規模、用途別（獣医病院、獣医クリニック、研究機関）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国...

進行型再発性多発性硬化症治療の世界市場（～2026年）

Global Progressive Relapsing Multiple Sclerosis Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY04381 2020年11月20日 97Pages
当調査資料は進行型再発性多発性硬化症治療のグローバル市場について調査・分析したレポートです。種類別（COG-133、GZ-402668、イネビリズマブ、VCE-0032、その他）市場規模、用途別（クリニック、病院、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、...

一次進行型多発性硬化症治療の世界市場（～2026年）

Global Primary Progressive Multiple Sclerosis Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY04371 2020年11月20日 92Pages
当調査資料は一次進行型多発性硬化症治療のグローバル市場について調査・分析したレポートです。種類別（ApE、ビオチン、GZ-402668、イブジラスト、イデベノン、ラキニモドナトリウム、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、...

二次性進行型多発性硬化症治療薬の世界市場（～2026年）

Global Secondary Progressive Multiple Sclerosis Drug Market Insights and Forecast to 2026
MRC2-11QY09340 2020年11月25日 151Pages
当調査資料は二次性進行型多発性硬化症治療薬のグローバル市場について調査・分析したレポートです。種類別（イネビリズマブ、GLX-1112、DC-TAB、エトモキシル、IB-MS、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス...

多発性骨髄腫治療薬の世界市場（～2026年）

Global Multiple Myeloma Therapeutics Market Size, Status and Forecast 2020-2026
MRC2-11QY03864 2020年11月20日 91Pages
当調査資料は多発性骨髄腫治療薬のグローバル市場について調査・分析したレポートです。種類別（化学療法・その他の薬剤、放射線、幹細胞移植、その他の支持療法）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本...

多系統萎縮症治療薬の世界市場（～2026年）

Global Multiple System Atrophy Therapeutics Market Insights and Forecast to 2026
MRC2-11QY07931 2020年11月20日 117Pages
当調査資料は多系統萎縮症治療薬のグローバル市場について調査・分析したレポートです。種類別（Anle-138b、AZD-3241、CS-10BR05、NPT-20011、PBT-434、PD-01）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フラン...

多発性骨髄腫に対するCAR-T細胞療法の世界市場（～2026年）

Global CAR T-Cell Therapy for Multiple Myeloma Market Size, Status and Forecast 2020-2026
MRC2-11QY11251 2020年11月25日 95Pages
当調査資料は多発性骨髄腫に対するCAR-T細胞療法のグローバル市場について調査・分析したレポートです。種類別（単剤療法、併用療法）市場規模、用途別（多発性骨髄腫、難治性/再発性多発性骨髄腫）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、...

筋萎縮性側索硬化症（ALS）治療の世界市場（～2026年）

Global Amyotrophic Lateral Sclerosis Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY10830 2020年11月25日 90Pages
当調査資料は筋萎縮性側索硬化症（ALS）治療のグローバル市場について調査・分析したレポートです。種類別（薬物療法、理学療法、言語療法、その他）市場規模、用途別（病院、専門センター、研究センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、ア...

筋萎縮性側索硬化症（ALS）の世界市場（～2026年）

Global Amyotrophic Lateral Sclerosis Market Size, Status and Forecast 2020-2026
MRC2-11QY10829 2020年11月25日 91Pages
当調査資料は筋萎縮性側索硬化症（ALS）のグローバル市場について調査・分析したレポートです。種類別（幹細胞治療、化学療法）市場規模、用途別（病院、診断センター、診療所、小売薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、...

多発性硬化症における幹細胞治療の世界市場（～2026年） Multiple sclerosis is a nervous system disease, triggered by unidentified environmental factors that adversely affects the brain and spinal cord. It damages the myelin sheath that surrounds and protects the nerve cells. Some of the symptoms of the disease includes weakness, numbness, blurred vision,…
多発性硬化症治療の世界市場（～2026年） Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a range of signs and symptoms, including physical, mental, and somet…
進行型再発性多発性硬化症治療の世界市場（～2026年） Market Analysis and Insights: Global Progressive Relapsing Multiple Sclerosis Treatment Market The global Progressive Relapsing Multiple Sclerosis Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Progressive R…
一次進行型多発性硬化症治療の世界市場（～2026年） Market Analysis and Insights: Global Primary Progressive Multiple Sclerosis Treatment Market The global Primary Progressive Multiple Sclerosis Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Primary Progressi…
二次性進行型多発性硬化症治療薬の世界市場（～2026年） Market Analysis and Insights: Global Secondary Progressive Multiple Sclerosis Drug Market The global Secondary Progressive Multiple Sclerosis Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Secondary Progressive M…